Replies to post #20253 on MindMaze Therapeutics Holding (RLFTF)

[trademax42]

Both NeruroRX and Relief sites state phase II/III trials:

"NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19"

https://www.neurorxpharma.com/press-releases/press-release-phase2-3covid-19/

"Phase IIb/III studies in Acute Respiratory Distress Syndrome induced by COVID-19"

https://relieftherapeutics.com/clinical-trials-2/

Also look at what the Chairman has said with regards to Phase IIb/III trials in a recent interview:

Let’s focus on the US: That is a Phase IIb/III trial that is aimed at patients who are severely ill because of the consequences of Covid-19. Assuming we have positive, statistically significant data, we would be in a position to go to the FDA and ask for approval. There is also a potential way to get approval sooner: This is by presenting the FDA clear evidence that the drug is therapeutically meaningful effective in a so-called compassionate access program. Having been granted the permission by the FDA to conduct such a compassionate access program, we are currently in this program. The study we are running has registrational quality. If it would be successful it could be the basis for a FDA approval.

https://themarket.ch/interview/relief-therapeutics-our-drug-could-generate-hundreds-of-millions-of-dollars-per-year-ld.2478


$RLFTF

Just my opinion of course, do your own dd.